Full Text View
Tabular View
No Study Results Posted
Related Studies
ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-Small Cell Lung Cancer (ZODIAC)
This study is ongoing, but not recruiting participants.
First Received: April 6, 2006   Last Updated: April 3, 2009   History of Changes
Sponsor: AstraZeneca
Information provided by: AstraZeneca
ClinicalTrials.gov Identifier: NCT00312377
  Purpose

This large phase III clinical study is studying the effect of vandetanib (ZACTIMA) in treating non-small cell lung cancer (NSCLC). Vandetanib is a new type of agent that targets the blood supply to a cancer tumour (through it's anti-VEGFR properties) and the tumour cells themselves (through it's anti-EGFR actions). This study will look at the effects of vandetanib in lung cancer patients who have had their cancer re-appear after treatment with standard chemotherapy.

This clinical study will test if the vandetanib anti-VEGF and anti-EGFR characteristics can deliver longer improved progression free survival and improved overall survival than docetaxel (Taxotere) alone.

All patients participating this clinical study will receive treatment with docetaxel, a commonly used treatment for recurrent non-small cell lung cancer.

In addition, some patients will also receive vandetanib (ZACTIMA), an anti-EGFR / anti-VEGF agent.

Recent clinical research shows that vascular endothelial growth factor receptor (VEGFR) inhibition, when used with standard chemotherapy, can lead to increased survival in advanced non-small cell lung cancer (NSCLC) patients.

Other research shows that epidermal growth factor receptor (EGFR) inhibitors, like erlotinib (Tarceva) can also increase overall non-small cell lung cancer survival by killing tumour cells and stopping them from dividing.


Condition Intervention Phase
Non-Small Cell Lung Cancer
Lung Cancer
 Drug: Docetaxel
Drug: Vandetanib
 Phase III

Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Phase III, Randomized, Double-Blinded, Multi-Center, Study to Assess the Efficacy of Docetaxel (TAXOTERE™) in Combination With ZD6474 (ZACTIMA™) Versus Docetaxel (TAXOTERE™) With Placebo in Subjects With Locally Advanced or Metastatic NSCLC

Resource links provided by NLM:

MedlinePlus related topics: Cancer Lung Cancer
Drug Information available for: Docetaxel Vandetanib
U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • The improvement in progression-free survival time for the vandetanib and docetaxel combination over docetaxel alone [ Time Frame: Treatment until death ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Demonstrate an improvement of overall survival for ZACTIMA™ in combination with docetaxel over docetaxel alone [ Time Frame: Treatment until death ] [ Designated as safety issue: No ]

Estimated Enrollment: 1240
Study Start Date: March 2006
Estimated Study Completion Date: August 2009
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Active Comparator
Docetaxel monotherapy
Drug: Docetaxel
oral
2: Experimental
Vandetanib + Docetaxel
Drug: Docetaxel
oral
Drug: Vandetanib
oral

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Lung cancer patients who answer true to the following statements are eligible to join this clinical study.

  • I have a confirmed diagnosis of locally advanced or metastatic non small cell lung cancer (Stage IIIb - IV)
  • I have had 1st line anti-cancer therapy. Previous treatment with Avastin (bevacizumab) in first line NSCLC is allowed.

Exclusion Criteria:

Lung cancer patients who answer true to the following are NOT eligible to join this clinical study.

  • I do not have non small cell lung cancer (NSCLC)
  • I have received treatment with docetaxel (Taxotere). Prior treatment with paclitaxel is acceptable.
  • I have received 2nd line anti-cancer therapy (For example, patients with previous 2nd line non small cell lung cancer (NSCLC) treatment with Tarceva (erlotinib, OSI-744), Alimta (pemetrexed) are not eligible)
  • I have been treated with VEGFR-TKIs (sunitinib, sorafenib, other VEGF TKIs). Previous treatment with Avastin (bevacizumab) in 1st line non small cell lung cancer is permitted.
  • I have a history of uncontrolled irregular heartbeat
  • I have a history of high blood pressure which has not been controlled with medication

If you are unsure of the meaning of the inclusion and exclusion criteria above, please contact the call center number for help.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00312377

  Hide Study Locations
Locations
United States, California
Research Site
FULLERTON, California, United States
Research Site
LAJOLLA, California, United States
Research Site
LONG BEACH, California, United States
Research Site
LOS ANGELES, California, United States
Research Site
NORTHRIDGE, California, United States
Research Site
POMONA, California, United States
Research Site
SANTA MARIA, California, United States
United States, Colorado
Research Site
COLORADO SPRINGS, Colorado, United States
United States, Connecticut
Research Site
NORWALK, Connecticut, United States
United States, Florida
Research Site
MIAMI BEACH, Florida, United States
Research Site
OCALA, Florida, United States
United States, Georgia
Research Site
LAWRENCEVILLE, Georgia, United States
Research Site
MARIETTA, Georgia, United States
United States, Illinois
Research Site
JOLIET, Illinois, United States
Research Site
PARK RIDGE, Illinois, United States
United States, Kansas
Research Site
HUTCHINSON, Kansas, United States
United States, Kentucky
Research Site
LOUISVILLE, Kentucky, United States
United States, Massachusetts
Research Site
BOSTON, Massachusetts, United States
Research Site
PITTSFIELD, Massachusetts, United States
United States, Michigan
Research Site
ANN ARBOR, Michigan, United States
United States, Missouri
Research Site
ST. LOUIS, Missouri, United States
United States, Nevada
Research Site
LAS VEGAS, Nevada, United States
United States, New York
Research Site
ALBANY, New York, United States
Research Site
ARMONK, New York, United States
Research Site
NEW YORK, New York, United States
Research Site
NORTHPORT, New York, United States
United States, North Carolina
Research Site
DURHAM, North Carolina, United States
Research Site
HICKORY, North Carolina, United States
Research Site
WINSTON-SALEM, North Carolina, United States
United States, Ohio
Research Site
CLEVELAND, Ohio, United States
United States, Oregon
Research Site
PORTLAND, Oregon, United States
United States, South Carolina
Research Site
GREENVILLE, South Carolina, United States
United States, Texas
Research Site
AUSTIN, Texas, United States
Research Site
HOUSTON, Texas, United States
United States, Utah
Research Site
OGDEN, Utah, United States
United States, Virginia
Research Site
ALEXANDRIA, Virginia, United States
Research Site
SALEM, Virginia, United States
Argentina
Research Site
CIUDAD DE BUENOS AIRES, Argentina
Research Site
MENDOZA, Argentina
Argentina, Buenos Aires
Research Site
BAHIA BLANCA, Buenos Aires, Argentina
Research Site
CAPITAL FEDERAL, Buenos Aires, Argentina
Argentina, SANTA FE
Research Site
ROSARIO, SANTA FE, Argentina
Austria
Research Site
GRAZ, Austria
Research Site
GRIMMENSTEIN, Austria
Research Site
LINZ, Austria
Research Site
WELS, Austria
Research Site
WIEN, Austria
Belgium
Research Site
LIEGE, Belgium
Research Site
BRUSSELS (WOLUWE-ST-LAMBERT), Belgium
Research Site
EDEGEM, Belgium
Research Site
GENK, Belgium
Research Site
BRUSSELS (JETTE), Belgium
Brazil, CE
Research Site
FORTALEZA, CE, Brazil
Brazil, GO
Research Site
GOIANIA, GO, Brazil
Brazil, RJ
Research Site
RIO DE JANEIRO, RJ, Brazil
Brazil, RS
Research Site
PORTO ALEGRE, RS, Brazil
Brazil, SP
Research Site
SAO PAULO, SP, Brazil
Canada
Research Site
QUEBEC, Canada
Canada, Alberta
Research Site
EDMONTON, Alberta, Canada
Canada, New Brunswick
Research Site
MONCTON, New Brunswick, Canada
Canada, Nova Scotia
Research Site
HALIFAX, Nova Scotia, Canada
Canada, Ontario
Research Site
KITCHENER, Ontario, Canada
Research Site
LONDON, Ontario, Canada
Research Site
TORONTO, Ontario, Canada
Canada, Quebec
Research Site
LAVAL, Quebec, Canada
China
Research Site
BEIJING, China
Research Site
NANJING, China
Research Site
SHANGHAI, China
Research Site
CHONG QING, China
China, GUANGDONG
Research Site
GUANGZHOU, GUANGDONG, China
China, HU BEI
Research Site
WUHAN, HU BEI, China
Denmark
Research Site
HERLEV, Denmark
Research Site
KOBENHAVN, Denmark
Research Site
ODENSE, Denmark
Research Site
ROSKILDE, Denmark
Research Site
VEJLE, Denmark
France
Research Site
BORDEAUX CEDEX, France
Research Site
BOULOGNE BILLANCOURT, France
Research Site
PIERRE BENITE CEDEX, France
Research Site
DIJON, France
Research Site
NANCY, France
Research Site
PARIS, France
Research Site
CAEN CEDEX, France
Research Site
SAINT HERBLAIN, France
Germany
Research Site
BAD BERKA, Germany
Research Site
BERLIN, Germany
Research Site
ESSEN, Germany
Research Site
GROBHANSDORF, Germany
Research Site
HALLE, Germany
Research Site
ULM, Germany
Research Site
HEIDELBERG, Germany
Research Site
KOLN, Germany
Research Site
OLDENBURG, Germany
Research Site
HAMBURG, Germany
Research Site
WIESBADEN, Germany
Greece
Research Site
115 22, Greece
Research Site
ATHENS, Greece
Research Site
HERAKLION, Greece
India
Research Site
INDIA, India
India, Andhra Pradesh
Research Site
HYDERABAD, Andhra Pradesh, India
India, GUJARAT
Research Site
AHMEDABAD, GUJARAT, India
India, KARNATAKA
Research Site
BANGALORE, KARNATAKA, India
India, MAHARASHTRA
Research Site
PUNE, MAHARASHTRA, India
India, TAMIL NADU
Research Site
CHENNAI, TAMIL NADU, India
Research Site
VELLORE, TAMIL NADU, India
India, WEST BENGAL
Research Site
KOLKATA, WEST BENGAL, India
Indonesia
Research Site
JAKARTA TIMUR, Indonesia
Indonesia, DIY
Research Site
YOGYAKARTA, DIY, Indonesia
Italy
Research Site
NAPOLI, Italy
Italy, ANCONA
Research Site
LE TORRETTE, ANCONA, Italy
Italy, AV
Research Site
AVELLINO, AV, Italy
Italy, BO
Research Site
BOLOGNA, BO, Italy
Italy, GE
Research Site
GENOVA, GE, Italy
Italy, MN
Research Site
MANTOVA, MN, Italy
Italy, PG
Research Site
PERUGIA, PG, Italy
Italy, PI
Research Site
PISA, PI, Italy
Italy, PR
Research Site
PARMA, PR, Italy
Italy, RE
Research Site
REGGIO EMILIA, RE, Italy
Italy, to
Research Site
ORBASSANO, to, Italy
Japan
Research Site
FUKUOKA, Japan
Research Site
KUMAMOTO, Japan
Research Site
OKAYAMA, Japan
Research Site
OSAKA, Japan
Japan, AICHI
Research Site
NAGOYA, AICHI, Japan
Research Site
OKAZAKI, AICHI, Japan
Japan, EHIME
Research Site
MATSUYAMA, EHIME, Japan
Japan, HOKKAIDO
Research Site
SAPPORO, HOKKAIDO, Japan
Japan, HYOGO
Research Site
AKASHI, HYOGO, Japan
Research Site
KOBE, HYOGO, Japan
Japan, KANAGAWA
Research Site
ISEHARA, KANAGAWA, Japan
Research Site
YOKOHAMA, KANAGAWA, Japan
Japan, OSAKA
Research Site
OSAKASAYAMA, OSAKA, Japan
Research Site
SAKAI, OSAKA, Japan
Research Site
TOYONAKA, OSAKA, Japan
Japan, SHIZUOKA
Research Site
SUNTO-GUN, SHIZUOKA, Japan
Japan, TOCHIGI
Research Site
UTSUNOMIYA, TOCHIGI, Japan
Japan, TOKYO
Research Site
KOTO-KU, TOKYO, Japan
Research Site
SHINJUKU, TOKYO, Japan
Japan, YAMAGUCHI
Research Site
UBE, YAMAGUCHI, Japan
Korea, Republic of
Research Site
SEOUL, Korea, Republic of
Malaysia
Research Site
PENANG, Malaysia
Malaysia, KELANTAN
Research Site
KUBANG KERIAN, KELANTAN, Malaysia
Malaysia, Negeri Sembilan
Research Site
NILAI, Negeri Sembilan, Malaysia
Mexico
Research Site
DURANGO, Mexico
Mexico, EDO DE MEX
Research Site
TOLUCA, EDO DE MEX, Mexico
Mexico, MICHOACAN
Research Site
MORELIA, MICHOACAN, Mexico
Netherlands
Research Site
AMSTERDAM, Netherlands
Research Site
GRONINGEN, Netherlands
Research Site
MAASTRICHT, Netherlands
Research Site
S-HERTOGENBOSCH, Netherlands
Portugal
Research Site
COIMBRA, Portugal
Research Site
FUNCHAL, Portugal
Research Site
LISBOA, Portugal
Research Site
PORTO, Portugal
Research Site
VILA NOVA DE GAIA, Portugal
Singapore
Research Site
SINGAPORE, Singapore
Spain, ANDALUCIA
Research Site
MALAGA, ANDALUCIA, Spain
Spain, ARAGON
Research Site
ZARAGOZA, ARAGON, Spain
Spain, Comunidad De Madrid
Research Site
MADRID, Comunidad De Madrid, Spain
Spain, Comunidad Valenciana
Research Site
ALICANTE, Comunidad Valenciana, Spain
Spain, GALICIA
Research Site
A CORUNA, GALICIA, Spain
Thailand
Research Site
CHIANG MAI, Thailand
Turkey
Research Site
ANKARA, Turkey
Research Site
ISTANBUL, Turkey
Research Site
IZMIR, Turkey
Vietnam
Research Site
HANOI CITY, Vietnam
Research Site
HO CHI MINH CITY, Vietnam
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: AstraZeneca Zactima Medical Science Director, MD AstraZeneca
  More Information

Additional Information:
AstraZeneca Clinical Trial Information - Outside US  This link exits the ClinicalTrials.gov site
US and Canda Only  This link exits the ClinicalTrials.gov site

No publications provided

Study ID Numbers: D4200C00032, 6474IL/0032
Study First Received: April 6, 2006
Last Updated: April 3, 2009
ClinicalTrials.gov Identifier: NCT00312377     History of Changes
Health Authority: United States: Food and Drug Administration

Keywords provided by AstraZeneca:
Non-small cell lung cancer
NSCLC

Additional relevant MeSH terms:
Thoracic Neoplasms
Respiratory Tract Neoplasms
Neoplasms by Histologic Type
Antineoplastic Agents
Pharmacologic Actions
Carcinoma
Docetaxel
Neoplasms
 Neoplasms by Site
Respiratory Tract Diseases
Lung Neoplasms
Therapeutic Uses
Lung Diseases
Carcinoma, Non-Small-Cell Lung
Neoplasms, Glandular and Epithelial

ClinicalTrials.gov processed this record on November 27, 2009



Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services